Drug Profile
Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft
Alternative Names: BioMed rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft; ORG 28077; rTSST-1 variant vaccine - Biomedizinische ForschungsgesellschaftLatest Information Update: 14 May 2020
Price :
$50
*
At a glance
- Originator Biomedizinische Forschungsgesellschaft
- Class Bacterial vaccines; Protein vaccines; Recombinant proteins; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bacterial infections
Most Recent Events
- 06 Feb 2020 Phase II development is ongoing in Austria
- 06 Feb 2020 Biomedizinische Forschungs completes a phase II trial in Bacterial infections (Prevention) in Austria (IM) (EudraCT2015-003714-24) (NCT02814708)
- 01 Oct 2019 Discontinued - Phase-II for Bacterial infections (Prevention) in Austria (IM)